Abstract
Manipulation of PPAR activity is often a valuable approach toward elucidation of the cellular effects of PPARs. The activity of specific PPARs can be decreased using chemical inhibitors, but these approaches can be affected by nonspecific interactions or cell toxicity. Alternative approaches include targeting PPAR gene expression or activity through molecular biology strategies. Here, we describe the targeting of PPARĪ³ through dominant-negative and siRNA-mediated knockdown constructs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARĪ³. Annu Rev Biochem 77:289ā312
Agostini M, Schoenmakers E, Mitchell C et al (2006) Non-DNA binding, dominant-negative, human PPARĪ³ mutations cause lipodystrophic insulin resistance. Cell Metab 4:303ā311
Barroso I, Gurnell M, Crowley V et al (1999) Dominant negative mutations in human PPARĪ³ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880ā883
Masugi J, Tamori Y, Kasuga M (1999) Inhibition of adipogenesis by a COOH-terminally truncated mutant of PPARĪ³2 in 3T3-L1 cells. Biochem Biophys Res Commun 264:93ā99
Ferguson HE, Kulkarni A, Lehmann G et al (2009) Electrophilic peroxisome proliferator-activated receptor-Ī³ ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol 41:722ā730
Gurnell M, Wentworth J, Agostini M et al (2000) A dominant-negative peroxisome proliferator-activated receptor Ī³ (PPARĪ³) mutant is a constitutive repressor and inhibits PPARĪ³-mediated adipogenesis. J Biol Chem 275:5754ā5759
Hata K, Nishimura R, Ikeda F et al (2003) Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis. Mol Biol Cell 14:545ā555
Park Y, Freedman B, Lee E et al (2003) A dominant negative PPARĪ³ mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. Diabetologia 46:365ā377
Wada K, Nakajima A, Katayama K et al (2006) Peroxisome proliferator-activated receptor Ī³-mediated regulation of neural stem cell proliferation and differentiation. J Biol Chem 281:12673ā12681
Semple RK, Meirhaeghe A, Vidal-Puig A et al (2005) A dominant negative human peroxisome proliferator-activated receptor (PPAR) Ī± is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms. Endocrinology 146:1871ā1882
Bastie C, Luquet S, Holst D et al (2000) Alterations of peroxisome proliferator-activated receptor Ī“ activity affect fatty acid-controlled adipose differentiation. J Biol Chem 275:38768ā38773
Nahle Z, Hsieh M, Pieka T et al (2008) CD36-dependent regulation of muscle FoxO1 and PDK4 in the PPARĪ“/Ī²-mediated Adaptation to Metabolic Stress. J Biol Chem 283:14317ā14326
Singh S, Bennett RG (2010) Relaxin signaling activates peroxisome proliferator-activated receptor gamma. Mol Cell Endocrinol 315:239ā245
Singh S, Bennett RG (2009) Relaxin family peptide receptor 1 activation stimulates peroxisome proliferator-activated receptor gamma. Ann N Y Acad Sci 1160:112ā116
Elbashir SM, Harborth J, Weber K et al (2002) Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26:199ā213
Liu J, Carmell M, Rivas F et al (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305:1437ā1441
Reynolds A, Leake D, Boese Q et al (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326ā330
Forman BM, Tontonoz P, Chen J et al (1995) 15-Deoxy-Ī12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARĪ³. Cell 83:803ā812
Palmer CNA, Hsu M, Griffin H et al (1995) Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 270:16114ā16121
Varanasi U, Chu R, Huang Q et al (1996) Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 271:2147ā2155
Jiang C, Ting AT, Seed B (1998) PPARĪ³ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82ā86
Dion LD, Fang J, Garver RI (1996) Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods 56:99ā107
Acknowledgments
Supported by funding through The Department of Veterans Affairs Biomedical Laboratory Research and Development Program, NIAAA (AA015509), and the Bly Memorial Research Fund (RGB), and by a University of Nebraska Medical Center Graduate College Fellowship (SS).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2013 Springer Science+Business Media New York
About this protocol
Cite this protocol
Singh, S., Bennett, R.G. (2013). Dominant-Negative and Knockdown Approaches to Studying PPAR Activity. In: Badr, M., Youssef, J. (eds) Peroxisome Proliferator-Activated Receptors (PPARs). Methods in Molecular Biology, vol 952. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-155-4_6
Download citation
DOI: https://doi.org/10.1007/978-1-62703-155-4_6
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-154-7
Online ISBN: 978-1-62703-155-4
eBook Packages: Springer Protocols